1st Cuneo City Immunotherapy Conference (CCITC)
Immunotherapy in Hematological Malignancies 2018

Cuneo, Centro Incontri, 17-19 Maggio 2018

Thursday, May 17, 2018

SESSION I: PASSIVE IMMUNOTHERAPY: TARGETING TUMOR CELLS

U. Vitolo

CD20 in lymphoma and chronic lymphocytic leukemia: groundwork and outlook

M. Boccadoro

CD38 in myeloma and beyond: groundwork & outlook

G. Martinelli

CD123 in leukemia and beyond: groundwork & outlook

G. Gaidano

In search of new markers in chronic lymphocytic leukemia and lymphoma

SESSION II: PASSIVE IMMUNOTHERAPY: ANTIBODY-DRUG CONJUGATES

S. Chiaretti

CD22: Inotuzumab ozogamicin

A. Pinto

CD30: Brentuximab vedotin

F. Gherlinzoni

CD33: Gemtuzumab ozogamicin

M. Martelli

CD79a: Polatuzumab vedotin

Friday, May 18, 2018

SESSION III: PASSIVE IMMUNOTHERAPY: TARGETING THE TUMOR MICROENVIRONMENT

A. Vacca

LECTURE: Tumor microenvironment in MM

N. Giuliani'

SLAMF7/CS1

F. Malavasi

CD38: “on target” “off tumor” effects

R. Ria

The DARPIN bispecific molecule

F. Di Raimondo

Role of aminoacids degrading enzymes in lympho-proliferative disease

M. Luppi

Key Points

SESSION IV: PASSIVE IMMUNOTHERAPY: TARGETING THE IMMUNE MICROENVIRONMENT

A. Santoro

PDI/PDL1 blockade in Hodgkin lymphoma

C. Stella

PDI/PDL1 blockade in non-Hodgkin lymphoma

B. Castella

Mechanisms of resistance to ICP blockade

G. Merlini

Targeting macrophages in amyloidosis

SESSION V: ADOPTIVE IMMUNOTHERAPY: IN VIVO RECRUITMENT

R. Bassan

Blinatumumab in ALL and beyond: groundwork and outlook

G. Inghirami

DART: groundwork and outlook

A. Filippi

Radiation and abscopal effect: lessons from solid tumors

SESSION VI: ADOPTIVE IMMUNOTHERAPY: EX-VIVO RECRUITMENT

A. Rambaldi

BET

L. Vago

Chimeric T cells

A. Bondanza

CAR-T

G. Casorati

CD1-restricted T cells

Saturday, 19 May, 2018

SESSION VII: IMMUNE LESSONS FROM ALLO-HSCT

F. Bonifazi

Transplantation trends in Italy: outcome and complications

A. Velardi

Alloreactivity of NK cells

A. Curti

Exploiting NK-cell alloreactivity in AML

F. Locatelli

γδ T cells and more in HLA-haploidentical HSCT

M. Bernardo

Mesenchimal Stem Cells

F. Aversa

Tolerance induction combining T-cell depletion and posttransplant cyclophosphamide in non-ablative haploidentical HSCT

SESSION VIII: TUMOR VACCINATION: WHERE WE STAND

A. Younes

LECTURE: Novel approaches of active immune therapy

R. Chiarle

ALK+ lymphomas and beyond

M. Massaia

Idiotypic vaccination: why we have failed 20 years ago